We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Bladder Cancer

Journal Scan / Research · April 11, 2022

Evaluation of ctDNA Using Sensitive Amplicon-Based NGS to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma

The Oncologist

 

Additional Info

The Oncologist
Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma
Oncologist 2022 Mar 16;[EPub Ahead of Print], P Ravi, A Ravi, IB Riaz, D Freeman, C Curran, C Mantia, BA McGregor, KL Kilbridge, CX Pan, M Pek, Y Choudhury, MH Tan, GP Sonpavde

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading